Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Scholar Rock Holding Corporation

The latest stock market stories for Tuesday are ready to go in the daily wrap-up.


Morning News Wrap-Up 3/31/26: Today’s Biggest Stock Market Stories!

Scholar Rock Holding stock rallied on Tuesday alongside plans to resubmit a BLA for its spinal muscular atrophy treatment.


	A	B	C	D
1	Symbol	Price	Change	Volume
2	SRRK	$50.10	+0.40%	907.04K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SRRK	$50.10	+0.4%	907.04K
3
4
5
6

SRRK

SRRK

Get Scholar Rock Holding Corporation Data in Excel

Get Scholar Rock Holding Corporation Data in Excel